SCHEMBL3583155

SCHEMBL3583155

CCOC(=O)c1ccc(C)nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CYP1A2 P05177 1/20 0.47
CASP1 P29466 1/20 0.47
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
HSD17B10 Q99714 1/20 0.45
EGFR P00533 4/20 0.44
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422881 0.86 TSHR (0.52) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL29550931 0.86 TSHR (0.52) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL31618845 0.85 TSHR (0.50) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL28704375 0.85 TSHR (0.50) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL22833338 0.85 ALDH1A1 (0.52) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL13072040 0.83 TSHR (0.49) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL7958076 0.83 TSHR (0.49) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL9355979 0.82 TSHR (0.55) TSHRALDH1A1KDM4EMEN1KMT2A
SCHEMBL334079 0.82 EGFR (0.50) TSHRKDM4ECA12CA1CA2
SCHEMBL5664007 0.82 KDM4E (0.57) TSHRALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136886-A PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof 中山大学 2025-06-13 CN claimed
CN-114163446-A Quinoline ketone skeleton PDE4 inhibitor and preparation method and application thereof 中山大学 2022-03-11 CN claimed
CN-120136886-A PDE4 inhibitor with pyranonaphthyridone skeleton and preparation method and application thereof 中山大学 2025-06-13 CN disclosed
CN-114163446-B PDE4 inhibitor with quinolinone skeleton and preparation method and application thereof 中山大学 2023-11-21 CN disclosed
CN-114163446-A Quinoline ketone skeleton PDE4 inhibitor and preparation method and application thereof 中山大学 2022-03-11 CN disclosed
CN-106316931-B 2-phenylnicotinic acid derivatives with insecticidal and acaricidal activity 沈阳中化农药化工研发有限公司 2020-05-05 CN disclosed
US-20200058883-A1 ORGANIC ELECTRIC LIGHT EMITTING ELEMENT, MATERIAL FOR SAID ELEMENT, AND LIGHT EMITTING DEVICE, DISPLAY DEVICE, AND ILLUMINATION DEVICE EMPLOYING SAID ELEMENT UDC IRELAND LTD (IE) 2020-02-20 US disclosed
US-10468607-B2 Organic electric light emitting element, material for said element, and light emitting device, display device, and illumination device employing said element UDC IRELAND LIMITED (IE) 2019-11-05 US disclosed
CN-110392681-A Tosylacetate-based compounds and derivatives thereof as PHGDH inhibitors 勃林格殷格翰国际有限公司 2019-10-29 CN disclosed
EP-2734526-B1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2016-04-06 EP disclosed
US-9221832-B2 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2015-12-29 US disclosed
CN-1162957-A Isoxazole derivatives SANKYO CO (JP) 1997-10-22 CN disclosed
EP-0779281-A1 ISOXAZOLES SANKYO COMPANY LIMITED (JP) 1997-06-18 EP disclosed
EP-0714393-A1 THIAZOLES AS ANTIVIRAL PFIZER INC. (US) 1996-06-05 EP disclosed
US-5493028-A Processes for producing 2-Halo-nicotinic acid derivatives and precursors thereto REILLY INDUSTRIES, INC. (US) 1996-02-20 US disclosed
WO-1995005378-A1 ANTIVIRAL THIAZOLES PFIZER INC. (US) 1995-02-23 WO disclosed
EP-0633880-A1 PROCESSES FOR PRODUCING 2-HALO-NICOTINIC ACID DERIVATIVES AND PRECURSORS THERETO REILLY INDUSTRIES, INC. (US) 1995-01-18 EP disclosed
US-5250548-A Treating hypertension, heart failure ABBOTT LABORATORIES (US) 1993-10-05 US disclosed
WO-1993018005-A2 PROCESSES FOR PRODUCING 2-HALO-NICOTINIC ACID DERIVATIVES AND PRECURSORS THERETO REILLY INDUSTRIES, INC. (US) 1993-09-16 WO disclosed
EP-0475206-A2 Angiotensin II receptor antagonists ABBOTT LABORATORIES (US) 1992-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10468607-B2 Organic electric light emitting element, material for said element, and light emitting device, display device, and illumination device employing said element L1CAM, NAP1L1, NOTCH1 TSHR 4611/4885ALDH1A1 120/4885KDM4E 2938/4885
US-20200058883-A1 ORGANIC ELECTRIC LIGHT EMITTING ELEMENT, MATERIAL FOR SAID ELEMENT, AND LIGHT EMITTING DEVICE, DISPLAY DEVICE, AND ILLUMINATION DEVICE EMPLOYING SAID ELEMENT NR0B1, NR2E1, NR1D1 TSHR 3963/4885ALDH1A1 227/4885KDM4E 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.